MarketCap
Facebook
X
TelegramGeschäftsbericht 2023
hinzugefügt 21.03.2024
Landos Biopharma Operativer Cashflow 2011-2026 | LABP
Operativer Cashflow Jährlich Landos Biopharma
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -20.5 M | -45.8 M | -27.1 M | -23 M | - | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| -20.5 M | -45.8 M | -29.1 M |
Operativer Cashflow Vierteljährlich Landos Biopharma
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | -8.17 M | - | -42.1 M | -34.5 M | -16.5 M | - | -15 M | -3.16 M | -12.6 M | - | -14.6 M | -9.19 M | -3.37 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| -3.16 M | -42.1 M | -15.9 M |
Operativer Cashflow anderer Aktien in der Pharmaeinzelhändler
| Name | Operativer Cashflow | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
Anavex Life Sciences Corp.
AVXL
|
-39 M | $ 3.02 | 1.0 % | $ 258 M |  USA |
 |
MorphoSys AG
MOR
|
-481 M | - | 2.43 % | $ 254 M |  Germany |
 |
BioNTech SE
BNTX
|
890 M | $ 90.9 | -0.31 % | $ 27.2 B | Germany |
 |
BioLineRx Ltd.
BLRX
|
-23.6 M | $ 2.34 | 5.72 % | $ 908 M |  Israel |
 |
I-Mab
IMAB
|
-1.3 B | - | - | $ 866 M |  China |
 |
Genfit SA
GNFT
|
99.9 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-23.8 M | - | -13.47 % | $ 169 M | France |
 |
Midatech Pharma plc
MTP
|
-6.01 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Codexis
CDXS
|
-19.4 M | $ 1.93 | 6.04 % | $ 168 M | USA |
 |
Cerus Corporation
CERS
|
4.84 M | $ 1.9 | 1.88 % | $ 362 M | USA |
 |
Acorda Therapeutics
ACOR
|
-14 M | - | -24.86 % | $ 820 K | USA |
 |
Cullinan Management
CGEM
|
-176 M | $ 15.2 | 5.34 % | $ 916 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-92.5 M | - | - | $ 86.2 M | USA |
 |
Advaxis
ADXS
|
-29.5 M | - | -9.65 % | $ 45.9 M | USA |
 |
Coherus BioSciences
CHRS
|
-139 M | $ 1.69 | -2.31 % | $ 198 M | USA |
 |
Applied Molecular Transport
AMTI
|
-93.9 M | - | - | $ 10.1 M | USA |
 |
Aeterna Zentaris
AEZS
|
-8.58 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
-18 M | - | -10.17 % | $ 12.2 K | USA |
 |
AIkido Pharma
AIKI
|
22.7 M | - | 1.93 % | $ 17.4 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-169 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-65.7 M | - | - | $ 26.5 M | USA |
 |
Akero Therapeutics
AKRO
|
-230 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
-63.7 M | - | 0.23 % | $ 488 M | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
-14.1 M | $ 0.46 | -13.46 % | $ 5.27 M | Israel |
 |
Allena Pharmaceuticals
ALNA
|
-45.7 M | - | 3.16 % | $ 1.9 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-43.8 M | - | - | $ 2.17 B | USA |
 |
Aileron Therapeutics
ALRN
|
-19.4 M | - | 10.36 % | $ 9.8 M | USA |
 |
Aquestive Therapeutics
AQST
|
-52.4 M | $ 4.11 | -0.48 % | $ 439 M | USA |
 |
CNS Pharmaceuticals
CNSP
|
-13.8 M | $ 2.27 | 0.39 % | $ 1.01 M | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
209 M | $ 24.91 | 0.89 % | $ 3.05 B | USA |
 |
Aravive
ARAV
|
-65.1 M | - | -13.39 % | $ 1.45 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
-74.3 M | $ 8.3 | 3.36 % | $ 227 M | Israel |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
-64.5 M | $ 10.37 | 1.97 % | $ 138 M | USA |
 |
Cardiff Oncology
CRDF
|
-37.9 M | $ 1.6 | 0.95 % | $ 107 M | USA |
 |
Curis
CRIS
|
-27.2 M | $ 0.53 | -3.64 % | $ 6.98 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
-378 M | $ 38.09 | 2.31 % | $ 3.58 B | USA |
 |
CRISPR Therapeutics AG
CRSP
|
-345 M | $ 49.43 | -0.17 % | $ 4.44 B |  Schweiz |
 |
Aptose Biosciences
APTO
|
-22 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
-59.7 M | - | -39.0 % | $ 4.57 M | USA |
 |
CytomX Therapeutics
CTMX
|
-75.6 M | $ 4.41 | -3.4 % | $ 608 M | USA |
 |
Citius Pharmaceuticals
CTXR
|
-28.2 M | $ 0.87 | 1.26 % | $ 5.85 M | USA |
 |
Cue Biopharma
CUE
|
-21.7 M | $ 0.17 | -7.12 % | $ 16.1 M | USA |
 |
CureVac N.V.
CVAC
|
-733 M | - | - | $ 867 M | Germany |
 |
AstraZeneca PLC
AZN
|
5.96 B | - | - | $ 96.9 B | Britain |
 |
Celldex Therapeutics
CLDX
|
-211 M | $ 31.43 | 1.18 % | $ 2.09 B | USA |
 |
Cyclerion Therapeutics
CYCN
|
-4.33 M | $ 4.34 | -29.51 % | $ 10.9 M | USA |
 |
Avenue Therapeutics
ATXI
|
-1.83 M | - | -52.27 % | $ 4.45 M | USA |